#1 Clinical Trials Search in Europe

Nepafenac

Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) used in ophthalmic treatments. This article examines various clinical trials investigating the efficacy and safety of Nepafenac in managing ocular conditions, particularly in relation to cataract surgery and diabetic macular edema. We’ll explore how Nepafenac compares to other treatments and its potential benefits in reducing inflammation and preventing complications in eye surgeries.

Table of Contents

What is Nepafenac?

Nepafenac is a medication used in eye care, specifically in the form of eye drops. It belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Nepafenac is known by various brand names, including Nevanac and Ilevro[1][2]. These eye drops are available in different concentrations, such as 0.1% and 0.3%[5].

Uses of Nepafenac

Nepafenac is primarily used for the following purposes:

  • Prevention and treatment of inflammation after cataract surgery: Nepafenac helps reduce swelling, redness, and pain in the eye following cataract removal[5].
  • Management of pain associated with cataract surgery: The medication can alleviate discomfort experienced after the procedure[5].
  • Prevention of macular edema: Nepafenac may help prevent the buildup of fluid in the macula (central part of the retina) after cataract surgery[4].
  • Treatment of diabetic macular edema: Some studies have explored its use in managing swelling in the macula caused by diabetes[9].

How Nepafenac Works

Nepafenac works by reducing the production of prostaglandins, which are substances in the body that cause inflammation. When applied to the eye, it helps decrease swelling, redness, and pain. Nepafenac is a “prodrug,” meaning it becomes active once it enters the eye and is converted to its active form, amfenac[5].

Administration

Nepafenac is typically administered as follows:

  • Frequency: Depending on the concentration and specific product, it may be used once daily (for 0.3% concentration) or three times daily (for 0.1% concentration)[5].
  • Duration: Treatment usually begins one day before cataract surgery and continues for up to 14 days after the procedure[5].
  • Additional dose: An extra dose may be given 30-120 minutes before the surgery[5].

Clinical Studies

Several clinical trials have been conducted to evaluate the effectiveness of Nepafenac:

  • Comparison with other NSAIDs: Studies have compared Nepafenac to other eye drops like bromfenac (Bromday, Prolensa) in terms of reducing inflammation after cataract surgery[2][6].
  • Different concentrations: Research has been done to compare the effectiveness of 0.1% and 0.3% Nepafenac formulations[5].
  • Macular edema prevention: Trials have investigated Nepafenac’s ability to prevent macular swelling in diabetic patients undergoing cataract surgery[4].
  • Non-central diabetic macular edema: A study explored the use of Nepafenac in treating macular edema that doesn’t involve the central part of the retina in diabetic patients[9].

Side Effects

While Nepafenac is generally well-tolerated, some potential side effects may include:

  • Increased eye pressure: In some cases, Nepafenac may cause a rise in intraocular pressure (the pressure inside the eye)[1].
  • Discomfort: Some patients may experience mild burning or stinging when applying the drops[10].
  • Allergic reactions: In rare cases, patients may develop an allergic response to the medication.

Comparison with Other Drugs

Nepafenac has been compared to other NSAIDs used in eye care:

  • Bromfenac: Studies have compared the effectiveness of Nepafenac and bromfenac in reducing inflammation after cataract surgery[2][6].
  • Diclofenac: Research has been conducted to compare patient comfort between Nepafenac and Diclofenac eye drops[10].

These comparisons help doctors and patients make informed decisions about which medication might be most suitable for individual cases.

Aspect Details
Primary Uses Prevention and treatment of inflammation and pain associated with cataract surgery
Formulations 0.1% and 0.3% ophthalmic suspensions
Dosing Regimens Varies by study: once daily (0.3%) or three times daily (0.1%), typically starting before surgery and continuing for 2-4 weeks after
Comparative Studies Compared with Bromfenac and placebo in various trials
Other Potential Applications Management of diabetic macular edema, reduction of macular thickening after pan-retinal photocoagulation, effects on intraocular pressure
Outcome Measures Intraocular inflammation, macular thickness, visual acuity, intraocular pressure, presence of cystoid macular edema
Safety Considerations Generally well-tolerated, but potential for ocular side effects should be monitored

FAQ

  • What is Nepafenac used for in eye treatments? Nepafenac is primarily used to prevent and treat inflammation and pain associated with cataract surgery. It's also being studied for its potential in managing diabetic macular edema and reducing intraocular pressure.
  • How is Nepafenac typically administered? Nepafenac is usually administered as eye drops. The dosage and frequency can vary, but common regimens include once daily (for 0.3% concentration) or three times daily (for 0.1% concentration), starting before cataract surgery and continuing for a few weeks after.
  • How does Nepafenac compare to other similar medications? Clinical trials have compared Nepafenac to other NSAIDs like Bromfenac. These studies aim to determine which medication is more effective in reducing inflammation and preventing complications after cataract surgery.
  • Are there any side effects associated with Nepafenac use? While specific side effects weren't detailed in the provided trials, NSAIDs like Nepafenac can potentially cause eye irritation, increased intraocular pressure, or other ocular effects. It's important to discuss potential side effects with your eye doctor.
  • Can Nepafenac help in conditions other than post-cataract surgery inflammation? Yes, research is exploring Nepafenac's potential in treating diabetic macular edema and reducing macular thickening after pan-retinal photocoagulation. It's also being studied for its effects on intraocular pressure in normal eyes.

Ongoing Clinical Trials on Nepafenac

  • Comparing the effectiveness of nepafenac and dexamethasone sodium phosphate for treating eye inflammation after cataract surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Reducing Inflammation After Cataract Surgery Using Nepafenac and Dexamethasone for Patients Undergoing Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Nepafenac and Dexamethasone for Reducing Inflammation and Swelling in Fuchs Dystrophy Patients After Corneal Transplant

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

Glossary

  • Nepafenac: A nonsteroidal anti-inflammatory drug (NSAID) used in ophthalmic treatments, primarily to reduce inflammation and pain after cataract surgery.
  • Intraocular Pressure: The fluid pressure inside the eye, which is important in the diagnosis and management of glaucoma.
  • Cataract: A clouding of the lens in the eye that affects vision, often treated with surgery.
  • Diabetic Macular Edema (DME): A complication of diabetes that causes swelling in the macula, the part of the retina responsible for detailed central vision.
  • Optical Coherence Tomography (OCT): A non-invasive imaging test that uses light waves to take cross-section pictures of the retina.
  • Phacoemulsification: A modern cataract surgery technique that uses ultrasound energy to break up the lens before removing it.
  • Macular Thickness: The measurement of the thickness of the macula, often used to assess the presence and severity of macular edema.
  • Pan-retinal Photocoagulation: A laser treatment for diabetic retinopathy that involves applying laser burns to the peripheral retina.
  • Aqueous Cells: White blood cells in the aqueous humor of the eye, indicating inflammation.
  • Aqueous Flare: Protein in the aqueous humor of the eye, another sign of inflammation.

References

  1. https://clinicaltrials.gov/study/NCT01995890
  2. https://clinicaltrials.gov/study/NCT01310127
  3. https://clinicaltrials.gov/study/NCT01657266
  4. https://clinicaltrials.gov/study/NCT00801905
  5. https://clinicaltrials.gov/study/NCT01318499
  6. https://clinicaltrials.gov/study/NCT03886779
  7. https://clinicaltrials.gov/study/NCT05331690
  8. https://clinicaltrials.gov/study/NCT00828477
  9. https://clinicaltrials.gov/study/NCT01331005
  10. https://clinicaltrials.gov/study/NCT02506348